A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Latest Information Update: 03 Mar 2026
At a glance
- Drugs GIA 632 (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Acronyms VITESS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 03 Mar 2026 New trial record